Look at the valuation of some of the PD-1 inhibitor companies. One of the value propositions from the R&D Day webcast was pairing SD101 with a PD-1 inhibitor. Companies in the cancer immunology space are seeing large valuations based on early stage trials. Different companies are also starting to partner to run combo-therapy drug trials in this space.
I think of the pipeline as the raffle ticket that you get for free when you buy shares in DVAX for a bet on Heplisav.
Does anyone have any knowledge or significance of this from the 14A:
The Fund has recently received notice that, at the upcoming annual meeting, Ironsides Partners Opportunity Master Fund L.P. (“Ironsides”), a shareholder of the Fund, intends to nominate non-incumbent candidates to serve as Trustees of the Fund (the “Ironsides Candidates”). Currently, there are no Ironsides-nominated Trustees on the Board. If nominated, neither the Board nor PIMCO believes that the election of the Ironsides Candidates is in the best interests of the Fund.
I had disposed of a rental property for a loss, causing my taxable income to drop. TurboTax calculated I was entitled to a $795 tax credit for my ACA policy. That was a pleasant shock.
Just a preview of what we could see if SD101 is successful in the cancer immunology space:
Kite's market cap has swelled to close to $2.7 billion as investors flocked to get in early on this new personalized approach to reengineering T cells into cancer fighters.
Looks like SD101 will be paired with Keytruda from Merck given the indication. If it works with Keytruda, I wonder if it would also work with Opdivo.
The FDA has accepted Bristol-Myers Squibb's ($BMY) application to get its star oncology treatment approved for lung cancer, setting up a speedy approval and putting the company first in line among drug developers at work in a blockbuster field.
With the acceptance, the agency has promised to hand down a final decision on Bristol-Myers' Opdivo by June 22, likely meaning the company will become the first maker of a so-called checkpoint inhibitor approved for lung cancer, beating out close rival Merck ($MRK). Bristol-Myers' treatment is designed to galvanize an immune system attack on tumors by blocking a pathway called PD-1, which, left unchecked, allows cancer cells to pass undetected by the body's natural defenses.
Like Merck's similar Keytruda, Opdivo won FDA approval last year as a treatment for melanoma, but lung cancer is widely considered to be the most promising--and most lucrative--application for PD-1 inhibitors. To that end, Merck is doing all it can to speed Keytruda along in the space, in January revealing that the drug was ahead of schedule and announcing plans to complete an FDA application by mid-2015. And thanks to the drug's "breakthrough" status at the FDA, it could pick up a lung cancer approval as soon as year's end, analysts figure.
Guess it could also be paired with Opdivo since that's also been recently approved for melanoma... in either case, if it's successful, lung cancer is next.
MACK and Silver Creek both got good mentions in the recently published book: Fast Forward: The Technologies and Companies Shaping Our Future. These are the guys that wrote Cracking The Code (Jim Melon and Al Chalabi) and they dedicated one chapter in the new book to biotech and life sciences. Seems they like Silver Creek and expect an IPO at some point.
Watch for the Summit Plc IPO. They've applied to the SEC for the IPO.
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo is the first and only PD-1 (programmed death receptor-1) therapy to demonstrate overall survival in previously treated metastatic squamous NSCLC. Opdivo demonstrated significantly superior overall survival (OS) vs. docetaxel, with a 41% reduction in the risk of death (hazard ratio: 0.59 [95% CI: 0.44, 0.79; p=0.00025]), in a prespecified interim analysis of a Phase III clinical trial. The median OS was 9.2 months in the Opdivo arm (95% CI: 7.3, 13.3) and 6 months in the docetaxel arm (95% CI: 5.1, 7.3).
It is part of the R&D day webcast. Look for presentations on the company web site for year 2014.
Analysts have speculated Opdivo will bring in peak sales of around $5 billion a year, and Leerink's Seamus Fernandez believes its promise in lung cancer will take that figure as high as $7.3 billion by 2020.
Thanks for laying that out. I figured by now that was obvious, but I guess not. It seems some of our posters are not watching or listening to the company's webcasts.
The onclive web site has a section on cancer immunology for anyone interested. There are a couple recent articles on pd-1 inhibitors, including the need to improve efficacy (relevant to SD-101).
When do you expect ARMOR2 to complete? Looks like patients are still being recruited for a study of three months duration from clinical trials website.
I'm looking at gradually starting a position in this stock sometime in 2015 for a 2016 play. I am curious why you would exit. I'm guessing you bought it as a short term momentum trade? Do you have issues with galeterone?
I'm looking to accumulate in 2015 for a long term cap gain at the end of 2016 when the phase 3 trial ends. At this point, I'm trying to get a handle on when ARMOR2 will be complete. It sounds like the phase3 trial protocol is already being developed (148 patients - seems small).
Full PDF can be downloaded. States 50% of new energy investment will go to renewables.
2 March 2015 – The ‘Financing the Future of Energy’ report launched yesterday at the Global Financial Markets Forum in Abu Dhabi, setting out the changing nature of the global energy system over the next decade and highlighting the growing demand for sustainable energy in the Gulf region.
Also NYTimes has new article about how utilities are fighting against rooftop solar with the help of the Koch Brothers, with successes in AZ and Wisconsin. (article titled: Utilities wage campaign against rooftop solar).
Read this article. Saudi Arabia taking market share fight downstream, gaining ‘growing captive market’ in Asia
And this one: Texas Refinery Is Saudi Foothold in U.S. Market